Otsuka a focused CNS company, and the producer of Abilify, purchased drug AVP-786 for $3.5 billion through their acquisition with Avanir on November 13, 2014. To get a sense of just how committed the company is to AVP-786, we have to look at the clinical trials that have started since the acquisition, and compare that to the number of clinical trials the company has started with another Otsuka drug Brexpiprazole, deemed the second generation drug of Abilify, that would compete in the indications similar to AVP-786.
Clinical Trials Started Since Acquisition
(3) Alzheimer's Agitation - U.S. phase 3
(1) Residual Schizophrenia phase 2
(1) Disinhibition phase 2
(1) Alzheimer's Agitation - Japan phase 3
Ongoing Trials With AVP-786
(1) Treatment Resistant Major Depression Disorder phase 2
New Otsuka Clinical Trials with Brexpiprazole
(0)
The company was previously in clinical trials prior to the acquisition of AVP-786, for Alzheimer's Agitation, MDD, and Schizophrenia as co- partner with Lundbeck. But has not initiated anything new since agreeing to acquire AVP-786 from Avanir late 2014.
Bottom Line: Some significance into the timing of initiating clinical trials, may help us identify a companies priority in their clinical pipeline. Thank you for reading.
Clinical Trials Started Since Acquisition
(3) Alzheimer's Agitation - U.S. phase 3
(1) Residual Schizophrenia phase 2
(1) Disinhibition phase 2
(1) Alzheimer's Agitation - Japan phase 3
Ongoing Trials With AVP-786
(1) Treatment Resistant Major Depression Disorder phase 2
New Otsuka Clinical Trials with Brexpiprazole
(0)
The company was previously in clinical trials prior to the acquisition of AVP-786, for Alzheimer's Agitation, MDD, and Schizophrenia as co- partner with Lundbeck. But has not initiated anything new since agreeing to acquire AVP-786 from Avanir late 2014.
Bottom Line: Some significance into the timing of initiating clinical trials, may help us identify a companies priority in their clinical pipeline. Thank you for reading.
No comments:
Post a Comment